Healthy Clinical Trial
Official title:
A First-in-Human, Phase I, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects, Including Food-Effect and Drug-drug Interaction With Itraconazole
Verified date | March 2023 |
Source | Kyorin Pharmaceutical Co.,Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and pharmacokinetics (PK) will be evaluated following administration of single and multiple doses of KRP-A218, including food-effect. In Part C, the drug-drug interaction (DDI) with itraconazole will be evaluated.
Status | Completed |
Enrollment | 99 |
Est. completion date | April 21, 2022 |
Est. primary completion date | April 21, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Key Inclusion Criteria: - Male or female adults, between 20 and 55 years of age, inclusive. - Body weight =50 kg, with body mass index (BMI) between 18.0 and 30.0 kg/m^2, inclusive. - In good health, at Screening or Day -1 as assessed by the Investigator. - Females will not be pregnant or lactating, and females of childbearing potential will agree to use contraception and to not donate eggs (ova, oocytes). Males will agree to use contraception and to not donate sperm. - Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions. Key Exclusion Criteria: - Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator. - Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing. - Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing. - Use or intend to use any prescription medications/products within 14 days or 5 half-lives (whichever is longer) prior to dosing, unless deemed acceptable by the Investigator. - Use or intend to use slow release medications/products considered to still be active within 14 days prior to dosing, unless deemed acceptable by the Investigator. - Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to dosing, unless deemed acceptable by the Investigator. - Use of tobacco or nicotine-containing products within 3 months prior to Day -1, or positive cotinine test at screening or Day -1. - Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to Day -1. - Consumption of caffeine- or xanthine-containing foods and beverages within 36 hours prior to Day -1. - Participation in strenuous exercised within 7 days prior to Day -1. - Receipt of blood products within 2 months prior to Day -1. - Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening. - Poor peripheral venous access. - Have previously completed or withdrawn from this study or have previously received the investigational medicinal product (IMP). - Subject is, in the opinion of the Investigator, unlikely to comply with the protocol or unsuitable to participate in this study for any reason. Other protocol defined Inclusion/Exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Labcorp Clinical Research | Leeds |
Lead Sponsor | Collaborator |
---|---|
Kyorin Pharmaceutical Co.,Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part A: Number of Participants With Adverse Events | A treatment-emergent adverse event (TEAE) was defined as an adverse event that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. Where a subject experienced multiple TEAEs with the same preferred term for the same treatment, this was counted as 1 TEAE for that treatment under the maximum severity recorded. |
Screening to follow-up (Approximately 6 weeks) | |
Primary | Part B: Number of Participants With Adverse Events | A treatment-emergent adverse event (TEAE) was defined as an adverse event that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. Where a subject experienced multiple TEAEs with the same preferred term for the same treatment, this was counted as 1 TEAE for that treatment under the maximum severity recorded. |
Screening to follow-up (Approximately 8 weeks) | |
Primary | Part C: Area Under Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-infinity) | The area under concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity) following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Area Under Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) | The area under concentration-time curve from time 0 extrapolated to last quantifiable concentration following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Maximum Observed Concentration (Cmax) | The maximum observed concentration following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Time of the Maximum Observed Concentration (Tmax) | The time of the maximum observed concentration following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Apparent Terminal Elimination Half-life (t1/2) | The apparent terminal elimination half-life following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Apparent Total Clearance (CL/F) | The apparent total clearance following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Primary | Part C: Apparent Volume of Distribution During the Terminal Phase (Vz/F) | The apparent volume of distribution during the terminal phase following Oral Dose Administration of KRP-A218 Alone and in Combination with Itraconazole | Days 1 to 11 | |
Secondary | Part A: Area Under Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-infinity) | Area under concentration-time curve from time 0 extrapolated to infinity following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Area Under Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) | Area under curve from time 0 to the time of the last quantifiable concentration following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Maximum Observed Concentration (Cmax) | Maximum observed concentration following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Time of the Maximum Observed Concentration (Tmax) | Time of the maximum observed concentration following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Apparent Terminal Elimination Half-life (t1/2) | Apparent terminal elimination half-life following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Apparent Total Clearance (CL/F) | Apparent total clearance following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part A: Apparent Volume of Distribution During the Terminal Phase (Vz/F) | Apparent volume of distribution during the terminal phase following single oral dose of KRP-A218 | Day 1 | |
Secondary | Part B: Area Under the Concentration-time Curve Over a Dosing Interval (AUC0-t) | Assessment of the area under the concentration-time curve over a dosing interval (AUC0-t) | Days 1 and 14 | |
Secondary | Part B: Area Under Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-infinity) | Assessment of the area under concentration-time curve from time 0 extrapolated to infinity (AUC0-infinity) | Day 1 | |
Secondary | Part B: Area Under Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) | Assessment of the area under curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) | Days 1 and 14 | |
Secondary | Part B: Maximum Observed Concentration (Cmax) | Assessment of the maximum observed concentration (Cmax) | Days 1 and 14 | |
Secondary | Part B: Minimum Observed Concentration (Cmin) | Assessment of the minimum observed concentration (Cmin) | Day 14 | |
Secondary | Part B: Time of the Maximum Observed Concentration (Tmax) | Assessment of the time of the maximum observed concentration (Tmax) | Days 1 and 14 | |
Secondary | Part B: Apparent Terminal Elimination Half-life (t1/2) | Assessment of the apparent terminal elimination half-life (t1/2) | Days 1 and 14 | |
Secondary | Part B: Apparent Total Clearance (CL/F) | Assessment of the apparent total clearance (CL/F) | Days 1 and 14 | |
Secondary | Part B: Apparent Volume of Distribution During the Terminal Phase (Vz/F) | Assessment of the apparent volume of distribution during the terminal phase (Vz/F) | Days 1 and 14 | |
Secondary | Part B: Observed Accumulation Ratio Based on Area Under the Concentration-Time Curve Over a Dosing Interval (ARAUC0-T) | Observed accumulation ratio based on area under the concentration-time curve over a dosing interval (ARAUC0-T) in Part B | Day 14 | |
Secondary | Part B: Observed Accumulation Ratio Based on Maximum Observed Concentration During the Dosing Interval (ARCmax) | Observed accumulation ratio based on maximum observed concentration during the dosing interval (ARCmax) in Part B | Day 14 | |
Secondary | Part C: Number of Participants With Adverse Events | A treatment-emergent adverse event (TEAE) was defined as an adverse event that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. Where a subject experienced multiple TEAEs with the same preferred term for the same treatment, this was counted as 1 TEAE for that treatment under the maximum severity recorded. |
Screening to follow-up (Approximately 7 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |